Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Stephan Schwers"'
Autor:
Tianxing Liu, Kensei Hashizume, Eva Krieg, Huijun Chen, Yuki Mukaida, Kirstin Thelen, Frauke Friedrichs, Stefan Willmann, Stephan Schwers, Alexander Solms, Rosie Yu
Publikováno v:
Clinical and Translational Science, Vol 17, Iss 4, Pp n/a-n/a (2024)
Abstract The inhibition of coagulation factor XI (FXI) presents an attractive approach for anticoagulation as it is not expected to increase the risk of clinically relevant bleeding and is anticipated to be at least as effective as currently availabl
Externí odkaz:
https://doaj.org/article/cb479031dd4144f68d40844bb322cbcc
Autor:
Alejandro Pallares Robles, Vincent ten Cate, Andreas Schulz, Jürgen H. Prochaska, Steffen Rapp, Thomas Koeck, Marina Panova-Noeva, Stefan Heitmeier, Stephan Schwers, Kirsten Leineweber, Hans-Jürgen Seyfarth, Christian F. Opitz, Henri Spronk, Christine Espinola-Klein, Karl J. Lackner, Thomas Münzel, Miguel A. Andrade-Navarro, Stavros V. Konstantinides, Hugo ten Cate, Philipp S. Wild
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-13 (2022)
Abstract Animal experiments and early phase human trials suggest that inhibition of factor XIa (FXIa) safely prevents venous thromboembolism (VTE), and specific murine models of sepsis have shown potential efficacy in alleviating cytokine storm. Thes
Externí odkaz:
https://doaj.org/article/a98f6fd0075b490c99854a9f91f37b80
Publikováno v:
Pharmaceuticals, Vol 5, Iss 3, Pp 279-296 (2012)
Dual antiplatelet therapy with acetylsalicylic acid and a thienopyridine, such as clopidogrel, is effective for the secondary prevention of cardiovascular events in patients with acute coronary syndrome, but there is still a substantial residual risk
Externí odkaz:
https://doaj.org/article/498ab589241a44c5940853c15c3ec74a
Publikováno v:
Journal of Thrombosis and Thrombolysis. 55:449-463
Rivaroxaban is a direct, oral factor Xa inhibitor that is used for the prevention and treatment of various thromboembolic disorders. Several preclinical and clinical studies have utilized specific molecules as biomarkers to investigate the potential
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::59ab85d47ea70de234cee463111bd0a4
https://doi.org/10.1007/s11239-023-02776-z
https://doi.org/10.1007/s11239-023-02776-z
Autor:
Dagmar Kubitza, Michael Heckmann, Jana Distler, Annemone Koechel, Stephan Schwers, Friederike Kanefendt
Publikováno v:
British Journal of Clinical Pharmacology. 88:3447-3462
To evaluate BAY 2433334, an oral activated factor XI (FXIa) inhibitor, in volunteers.Phase 1 study of healthy men at a German centre. Part A: randomized, single-blind, multiple dose-escalation study of BAY 2433334 (25/50/100 mg once daily [OD]) vs. p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff4430d488991103ddc638747727c02c
https://doi.org/10.1111/bcp.15230
https://doi.org/10.1111/bcp.15230
Autor:
Stephan Schwers, Julia Mueller, Peter Turecek, Nikolaus B Binder, Matthias Germer, François Depasse, Björn Hermes, Thomas Dr. Wissel
Publikováno v:
Journal of Thrombosis and Haemostasis. 19:2907-2917
Thrombin is the pivotal enzyme in the biochemistry of secondary hemostasis crucial to maintaining homeostasis of hemostasis. In contrast to routine coagulation tests (PT or aPTT) or procoagulant or anticoagulant factor assays (e.g. fibrinogen, factor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23868980f4495123f3866eefc501b532
https://doi.org/10.1111/jth.15529
https://doi.org/10.1111/jth.15529
Autor:
François Depasse, Peter Turecek, Thomas Dr. Wissel, Julia Mueller, Björn Hermes, Matthias Germer, Nikolaus B Binder, Stephan Schwers
Publikováno v:
Journal of Thrombosis and Haemostasis. 19:2918-2929
Determining patient's coagulation profile, i.e. detecting a bleeding tendency or the opposite, a thrombotic risk, is crucial for clinicians in many situations. Routine coagulation assays and even more specialized tests may not allow a relevant charac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d5f8d43e10f2b7d3d7a2ae8bb56fa1c
https://doi.org/10.1111/jth.15538
https://doi.org/10.1111/jth.15538
Autor:
Friederike Kanefendt, Stephan Schwers, Ashraf Yassen, Stefanie Boxnick, Sigrun Unger, Dirk Thomas
Publikováno v:
Journal of Thrombosis and Haemostasis
Background Coagulation factor XI (FXI) contributes to the development of thrombosis but appears to play a minor role in hemostasis and is, therefore, an attractive anticoagulant drug target. Objectives To evaluate the safety, pharmacokinetic and phar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b686f12b3df9f01ac70161a7000a13c6
https://doi.org/10.1111/jth.15439
https://doi.org/10.1111/jth.15439
Subtype-specific plasma signatures of platelet-related protein releasate in acute pulmonary embolism
Autor:
Gaukhar Baidildinova, Vincent ten Cate, Markus Nagler, Marina Panova-Noeva, Steffen Rapp, Thomas Köck, Jürgen H. Prochaska, Stefan Heitmeier, Christoph Gerdes, Stephan Schwers, Stavros Konstatinides, Thomas Münzel, Christine Espinola-Klein, Karl J. Lackner, Henri M.N. Spronk, Hugo ten Cate, Paola E.J. van der Meijden, Kirsten Leineweber, Philipp S. Wild, Kerstin Jurk
Publikováno v:
Thrombosis Research, 220, 75-87. Elsevier Science
INTRODUCTION: There is evidence that plasma protein profiles differ in the two subtypes of pulmonary embolism (PE), isolated PE (iPE) and deep vein thrombosis (DVT)-associated PE (DVT-PE), in the acute phase. The aim of this study was to determine sp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51f4536f28a40718c64325a1964f59db
https://pubmed.ncbi.nlm.nih.gov/36274391
https://pubmed.ncbi.nlm.nih.gov/36274391
Autor:
Bettina Nowotny, Dirk Thomas, Stephan Schwers, Sara Wiegmann, Wolfgang Prange, Ashraf Yassen, Stefanie Boxnick
Publikováno v:
Journal of thrombosis and haemostasis : JTH. 20(7)
Bleeding is a clinically significant issue with all current anticoagulants. Safer antithrombotic strategies are required.To investigate the safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, a humanized, factor XI (FXI)-directed monoclona
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96979c968b418096abd382db4e448968
https://pubmed.ncbi.nlm.nih.gov/35490404
https://pubmed.ncbi.nlm.nih.gov/35490404